Modality
Small Molecule
MOA
C5i
Target
GIP-R
Pathway
JAK/STAT
Parkinson's
Development Pipeline
Preclinical
~Nov 2019
→ ~Feb 2021
Phase 1
May 2021
→ Sep 2028
Phase 1Current
NCT06468830
146 pts·Parkinson's
2021-05→2028-09·Not yet recruiting
NCT07333612
2,718 pts·Parkinson's
2021-07→2025-11·Recruiting
2,864 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-284mo agoPh2 Data· Parkinson's
2028-09-222.5y awayPh2 Data· Parkinson's
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1/2
Not yet…
P1/2
Recruit…
Catalysts
Ph2 Data
2025-11-28 · 4mo ago
Parkinson's
Ph2 Data
2028-09-22 · 2.5y away
Parkinson's
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06468830 | Phase 1/2 | Parkinson's | Not yet recr... | 146 | BodyWt |
| NCT07333612 | Phase 1/2 | Parkinson's | Recruiting | 2718 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 | |
| TNG-8610 | Tango Ther | NDA/BLA | GIP-R |